Nanobodies: The potential application in bacterial treatment and diagnosis

Yu, Siyuan; Zhang, Lu; Wang, Aihua; Jin, Yaping; Zhou, Dong

doi:10.1016/j.bcp.2023.115640

Cited by 12 publications

(4 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar approach can be used to obtain therapeutic nanobodies (ai-Nbs) against T3SS components of other pathogenic microorganisms. In a number of studies, anti-infective nanobodies were obtained that bind to pathogen surface structures, components of secretion and transport systems [44][45][46][47][48]. We hope that the ai-Nb-based method described in this paper could be applied to obtaining biomimetics of "sensitive" pathogenic epitopes of these nanobodies, as well to their use in possible therapeutic directed immunomodulation of the host immune system.…”

Section: Discussionmentioning

confidence: 98%

Anti-Idiotypic Nanobodies Mimicking an Epitope of the Needle Protein of the Chlamydial Type III Secretion System for Targeted Immune Stimulation

Koroleva,

Goryainova,

Ivanova

et al. 2024

IJMS

View full text Add to dashboard Cite

The development of new approaches and drugs for effective control of the chronic and complicated forms of urogenital chlamydia caused by Chlamydia trachomatis, which is suspected to be one of the main causes of infertility in both women and men, is an urgent task. We used the technology of single-domain antibody (nanobody) generation both for the production of targeting anti-chlamydia molecules and for the subsequent acquisition of anti-idiotypic nanobodies (ai-Nbs) mimicking the structure of a given epitope of the pathogen (the epitope of the Chlamydial Type III Secretion System Needle Protein). In a mouse model, we have shown that the obtained ai-Nbs are able to induce a narrowly specific humoral immune response in the host, leading to the generation of intrinsic anti-Chlamydia antibodies, potentially therapeutic, specifically recognizing a given antigenic epitope of Chlamydia. The immune sera derived from mice immunized with ai-Nbs are able to suppress chlamydial infection in vitro. We hypothesize that the proposed method of the creation and use of ai-Nbs, which mimic and present to the host immune system exactly the desired region of the antigen, create a fundamentally new universal approach to generating molecular structures as a part of specific vaccine for the targeted induction of immune response, especially useful in cases where it is difficult to prepare an antigen preserving the desired epitope in its native conformation.

show abstract

Section: Discussionmentioning

confidence: 98%

Anti-Idiotypic Nanobodies Mimicking an Epitope of the Needle Protein of the Chlamydial Type III Secretion System for Targeted Immune Stimulation

Koroleva,

Goryainova,

Ivanova

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Nanobodies offer several advantages, including reduced immunogenicity, the ability to bind to hidden epitopes due to their small size, high water solubility, strong affinity for their targets, and the ability to be expressed in a variety of expression systems (e.g., Escherichia coli and yeast). 9,10 Traditional techniques for identifying broad-spectrum nanobodies encompass the enzyme-linked immunosorbent assay (ELISA) and pseudovirus-based neutralization assays. 11−16 For example, in 2020, Wrapp et al isolated and prepared a bivalent nanobody (VHH-72-Fc) that effectively neutralizes SARS-CoV-2 S pseudoviruses through ELISA.…”

Section: ■ Introductionmentioning

confidence: 99%

“…In comparison to the human IgG antibody (150 kDa), the nanobody is significantly smaller, ranging from 12 to 15 kDa. Nanobodies offer several advantages, including reduced immunogenicity, the ability to bind to hidden epitopes due to their small size, high water solubility, strong affinity for their targets, and the ability to be expressed in a variety of expression systems (e.g., Escherichia coli and yeast). , …”

Section: Introductionmentioning

confidence: 99%

Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization

Zhang,

Huang,

Zhang

et al. 2024

J. Proteome Res.

View full text Add to dashboard Cite

The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the emergence of different variants of concerns with immune evasion that have been prevalent over the past three years. Nanobodies, the functional variable regions of camelid heavy-chain-only antibodies, have garnered interest in developing neutralizing antibodies due to their smaller size, structural stability, ease of production, high affinity, and low immunogenicity, among other characteristics. In this work, we describe an integrated proteomics platform for the high-throughput screening of nanobodies against different SARS-CoV-2 spike variants. To demonstrate this platform, we immunized a camel with subunit 1 (S1) of the wild-type spike protein and constructed a nanobody phage library. The binding and neutralizing activities of the nanobodies against 72 spike variants were then measured, resulting in the identification of two nanobodies (C-282 and C-39) with broad neutralizing activity against six non-Omicron variants (D614G, Alpha, Beta, Gamma, Delta, Kappa) and five Omicron variants (BA.1−5). Their neutralizing capability was validated using in vitro pseudovirus-based neutralization assays. All these results demonstrate the utility of our proteomics platform to identify new nanobodies with broad neutralizing capability and to develop a treatment for patients with SARS-CoV-2 variant infection in the future.

show abstract

“…For example, the method based on microbial culture has a long culture time (48-72 h) and is susceptible to contamination [13]. Antibody detection requires a large number of antigens, and the accuracy of the results is unstable, prone to false positives, and takes a long time [14]. Multiple polymerase chain reaction (PCR)-based molecular diagnostics and mass spectrometry require a high level of expertise and equipment for testing [15].…”

Section: Introductionmentioning

confidence: 99%

Recent Strategies to Develop Conjugated Polymers for Detection and Therapeutics

Li,

Qi,

Wang

et al. 2023

Polymers

View full text Add to dashboard Cite

The infectious diseases resulting from pathogenic microbes are highly contagious and the source of infection is difficult to control, which seriously endangers life and public health safety. Although the emergence of antibiotics has a good therapeutic effect in the early stage, the massive abuse of antibiotics has brought about the evolution of pathogens with drug resistance, which has gradually weakened the lethality and availability of antibiotics. Cancer is a more serious disease than pathogenic bacteria infection, which also threatens human life and health. Traditional treatment methods have limitations such as easy recurrence, poor prognosis, many side effects, and high toxicity. These two issues have led to the exploration and development of novel therapeutic agents (such as conjugated polymers) and therapeutic strategies (such as phototherapy) to avoid the increase of drug resistance and toxic side effects. As a class of organic polymer biological functional materials with excellent photoelectric properties, Conjugated polymers (CPs) have been extensively investigated in biomedical fields, such as the detection and treatment of pathogens and tumors due to their advantages of easy modification and functionalization, good biocompatibility and low cost. A rare comprehensive overview of CPs-based detection and treatment applications has been reported. This paper reviews the design strategies and research status of CPs used in biomedicine in recent years, introduces and discusses the latest progress of their application in the detection and treatment of pathogenic microorganisms and tumors according to different detection or treatment methods, as well as the limitations and potential challenges in prospective exploration.

show abstract

Nanobodies: The potential application in bacterial treatment and diagnosis

Cited by 12 publications

References 157 publications

Anti-Idiotypic Nanobodies Mimicking an Epitope of the Needle Protein of the Chlamydial Type III Secretion System for Targeted Immune Stimulation

Anti-Idiotypic Nanobodies Mimicking an Epitope of the Needle Protein of the Chlamydial Type III Secretion System for Targeted Immune Stimulation

Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization

Recent Strategies to Develop Conjugated Polymers for Detection and Therapeutics

Contact Info

Product

Resources

About